191 related articles for article (PubMed ID: 16176921)
21. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development.
Larcher F; Murillas R; Bolontrade M; Conti CJ; Jorcano JL
Oncogene; 1998 Jul; 17(3):303-11. PubMed ID: 9690512
[TBL] [Abstract][Full Text] [Related]
22. Cytogenetic analysis of malignant skin tumors induced in chemically treated TG-AC transgenic mice.
French JE; Libbus BL; Hansen L; Spalding J; Tice RR; Mahler J; Tennant RW
Mol Carcinog; 1994 Dec; 11(4):215-26. PubMed ID: 7999263
[TBL] [Abstract][Full Text] [Related]
23. Blue light inhibits the growth of skin tumors in the v-Ha-ras transgenic mouse.
Ohara M; Kawashima Y; Kitajima S; Mitsuoka C; Watanabe H
Cancer Sci; 2003 Feb; 94(2):205-9. PubMed ID: 12708498
[TBL] [Abstract][Full Text] [Related]
24. Loss of critical palindromic transgene promoter sequence in chemically induced Tg.AC mouse skin papillomas expressing transgene-derived mRNA.
Thompson KL; Rosenzweig BA; Honchel R; Cannon RE; Blanchard KT; Stoll RE; Sistare FD
Mol Carcinog; 2001 Dec; 32(4):176-86. PubMed ID: 11746829
[TBL] [Abstract][Full Text] [Related]
25. Association of gene expression with sequential proliferation, differentiation and tumor formation in murine skin.
Ridd K; Zhang SD; Edwards RE; Davies R; Greaves P; Wolfreys A; Smith AG; Gant TW
Carcinogenesis; 2006 Aug; 27(8):1556-66. PubMed ID: 16537558
[TBL] [Abstract][Full Text] [Related]
26. Homozygous K5Cre transgenic mice have wavy hair and accelerated malignant progression in a murine model of skin carcinogenesis.
Chan EL; Peace BE; Toney K; Kader SA; Pathrose P; Collins MH; Waltz SE
Mol Carcinog; 2007 Jan; 46(1):49-59. PubMed ID: 17013830
[TBL] [Abstract][Full Text] [Related]
27. Squamous cell hyperplastic foci: precursors of cutaneous papillomas induced in SENCAR mice by a two-stage carcinogenesis regimen.
Binder RL; Johnson GR; Gallagher PM; Stockman SL; Sundberg JP; Conti CJ
Cancer Res; 1998 Oct; 58(19):4314-23. PubMed ID: 9766659
[TBL] [Abstract][Full Text] [Related]
28. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice.
Spalding JW; French JE; Tice RR; Furedi-Machacek M; Haseman JK; Tennant RW
Toxicol Sci; 1999 Jun; 49(2):241-54. PubMed ID: 10416269
[TBL] [Abstract][Full Text] [Related]
29. Dermal carcinogenicity in transgenic mice: relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12-O-tetradecanoylphorbol 13-acetate (TPA) and benzene.
Blanchard KT; Ball DJ; Holden HE; Furst SM; Stoltz JH; Stoll RE
Toxicol Pathol; 1998; 26(4):541-7. PubMed ID: 9715513
[TBL] [Abstract][Full Text] [Related]
30. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
31. IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis.
Murphy JE; Morales RE; Scott J; Kupper TS
J Immunol; 2003 Jun; 170(11):5697-703. PubMed ID: 12759452
[TBL] [Abstract][Full Text] [Related]
32. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
33. Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53.
Zhang Z; Yao R; Li J; Wang Y; Boone CW; Lubet RA; You M
Mol Cancer Res; 2005 Oct; 3(10):563-74. PubMed ID: 16254190
[TBL] [Abstract][Full Text] [Related]
34. 12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mouse epidermis coexpressing transforming growth factor-alpha and v-fos: acceleration of autonomous papilloma formation and malignant conversion via c-Ha-ras activation.
Wang XJ; Liefer KM; Greenhalgh DA; Roop DR
Mol Carcinog; 1999 Dec; 26(4):305-11. PubMed ID: 10569807
[TBL] [Abstract][Full Text] [Related]
35. Dose-dependent mutation profile in the c-Ha-ras proto-oncogene of skin tumors in mice initiated with benzo[a]pyrene.
Wei SJ; Chang RL; Merkler KA; Gwynne M; Cui XX; Murthy B; Huang MT; Xie JG; Lu YP; Lou YR; Jerina DM; Conney AH
Carcinogenesis; 1999 Sep; 20(9):1689-96. PubMed ID: 10469612
[TBL] [Abstract][Full Text] [Related]
36. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.
Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA
Cancer Res; 2006 Feb; 66(3):1302-12. PubMed ID: 16452183
[TBL] [Abstract][Full Text] [Related]
37. Association of tumor development with increased cellular proliferation and transgene overexpression, but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice.
Hansen LA; Trempus CS; Mahler JF; Tennant RW
Carcinogenesis; 1996 Sep; 17(9):1825-33. PubMed ID: 8824502
[TBL] [Abstract][Full Text] [Related]
38. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha.
Greenhalgh DA; Wang XJ; Donehower LA; Roop DR
Cancer Res; 1996 Oct; 56(19):4413-23. PubMed ID: 8813135
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis.
La E; Muga SJ; Locniskar MF; Fischer SM
Mol Carcinog; 1999 Apr; 24(4):276-86. PubMed ID: 10326864
[TBL] [Abstract][Full Text] [Related]
40. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis.
Wang XJ; Greenhalgh DA; Jiang A; He D; Zhong L; Medina D; Brinkley BR; Roop DR
Oncogene; 1998 Jul; 17(1):35-45. PubMed ID: 9671312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
